NSF awards grant to DMC Biotechnologies for high throughput metabolic engineering platform development.

November 10, 2017 |

In Colorado, DMC Biotechnologies was awarded a National Science Foundation Small Business Innovation Research Phase II grant for $600,000 to commercialize their proprietary high throughput metabolic engineering platform that enables the rapid development of microbial hosts for the production of a broad diversity of bio-based products.  The comapny also recently picked up a National Institute of Food and Agriculture SBIR phase one grant for $100,000 and was selected for Maine’s Born Global Challenge.

The company sports ‘novel, patent-pending technology for rapid engineering of robust microbial hosts’.  According to DMC, “deployment of Dynamic Metabolic Control technology dramatically reduces the cost and development timeline from discovery to commercial performance. Our ultra low cost development will democratize metabolic engineering efforts, creating a multitude of commercially viable bioprocesses and delivering sustainable routes to both new and existing products. including a  broad diverse aray of specialty chemicals, flavors, fragrances, neutracueticals, natural products, pharmaceuticals, and APIs.”

“The vision for DMC is to develop bio-based processes that are superior in cost and quality to existing manufacturing routes. We are extremely pleased to be recognized with this highly competitive award from the NSF and are grateful for their continued support of our mission.  This SBIR grant plays a vital role in advancing our technology along the commercial path,” said CEO Matt Lipscomb.

More on the story.

Tags:

Category: Research

Comments are closed.